Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA’s New Chief Of Staff Suggested Greater Authority On Nano-Supplements

This article was originally published in The Tan Sheet

Executive Summary

FDA’s new chief of staff has recommended pre-market registration and testing of products with nanoparticles and post-market reviews of nano-engineered supplement ingredients.

You may also be interested in...



Consumer Groups Back FDA On NDI Draft Guidance

The Consumers Union and National Consumers League suggest requiring NDI notifications for all nano-engineered supplements. The groups support FDA’s assertion that each NDI-containing supplement needs a notification, with CU saying industry’s NDI record is “grossly unfair to consumers.”

Consumer Groups Back FDA On NDI Draft Guidance

The Consumers Union and National Consumers League suggest requiring NDI notifications for all nano-engineered supplements. The groups support FDA’s assertion that each NDI-containing supplement needs a notification, with CU saying industry’s NDI record is “grossly unfair to consumers.”

FDA Becomes An Agency Of “Directorates” Under Hamburg’s Reorganization

Commissioner Margaret Hamburg’s structural reorganization of FDA leaves the current leadership of the agency’s centers intact, but adds a new layer of management and accountability between the medical product center directors and the commissioner’s office.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS105411

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel